ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will report its first quarter 2014 financial results on Wednesday, May 7, 2014, before the market opens. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares after opening at $7.62 moved to $7.72 on last trade day and at the end of the day closed at $7.45. Company price to sales ratio in past twelve months was calculated as 30.44 and price to cash ratio as 5.85. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive weekly performance of 4.93%.
Gilead Sciences, Inc. (NASDAQ:GILD) Net income for the first quarter of 2014 was $2.23 billion, or $1.33 per diluted share compared to $722.2 million, or $0.43 per diluted share for the first quarter of 2013. Gilead Sciences, Inc. (NASDAQ:GILD) shares advanced 0.30% in last trading session and ended the day on $74.08. GILD return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 46.49%.
Amgen Inc. (NASDAQ:AMGN) the world’s largest biotechnology company by sales, reported first-quarter revenue below analysts’ estimates on lower-than-expected demand of its top drug, Enbrel. Amgen, Inc. (NASDAQ:AMGN) shares moved up 0.36% in last trading session and was closed at $113.72, while trading in range of $111.79 – $114.50. Amgen, Inc. (NASDAQ:AMGN) year to date (YTD) performance is 0.19%.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) weekly performance is -2.06%. On last trading day company shares ended up $6.17. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is -6.12%. Analysts mean target price for the company is $7.83.